Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.
Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease